MacarenaInesDe La FuenteMD

Neurooncology

Physician

Dr. De La Fuente is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1120 Nw 14th St
Miami, FL 33136
Phone+1 305-243-4951

Fax+1 305-243-7432

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors Start of enrollment: 2020 Jun 16
Terminated
Phase 1
Roles: Principal Investigator, Contact
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment Start of enrollment: 2024 Jan 04
Recruiting
Phase 2
Roles: Principal Investigator, Contact
STARLITE for Unresectable High-Grade Gliomas Start of enrollment: 2024 Aug 31
Not yet recruiting
Phase 1
Roles: Contact, Principal Investigator

PubMed

136 citations
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma
Macarena I. de la Fuente, Robert J. Young, Jennifer Rubel, Marc K. Rosenblum, Jamie Tisnado
Neuro-Oncology. 2016-02-01
143 citations
Ivosidenib in Isocitrate Dehydrogenase 1 - Mutated Advanced Glioma.
Ingo K. Mellinghoff, Benjamin M. Ellingson, Mehdi Touat, Elizabeth A. Maher, Macarena I. de la Fuente
Journal of Clinical Oncology. 2020-06-12
73 citations
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
Lillian M. Smyth, Sarina Anne Piha-Paul, Helen Won, Alison M. Schram, Cristina Saura
Cancer Discovery. 2020-02-01